Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS12P24 is a processed pseudogene derived from the **ribosomal protein S12** gene (RPS12). Pseudogenes are genomic DNA sequences similar to normal genes but nonfunctional; they result from gene duplication or retrotransposition events followed by disabling mutations that prevent protein expression[8]. RPS12P24 does not produce a protein nor does it encode any known biological function or disease association. While its parent gene, ribosomal protein S12, is essential for ribosomal function and protein synthesis[5][6], RPS12P24 itself is considered *genomic "junk"* or "dead" gene sequence with no role as a therapeutic target, biomarker, or disease-relevant molecule[8]. For molecular targeting, functional RPS12 would be the relevant entity—not its pseudogene copies dispersed throughout the genome[5][6][7][8]. **Detailed context on parent gene (RPS12):** - RPS12 encodes ribosomal protein S12, which is a structural component of the small 40S ribosomal subunit and functions in translation, codon recognition, and accuracy of protein synthesis[1][5][6]. - The human genome contains many processed pseudogenes of ribosomal protein genes, including RPS12P24, which typically do not have coding or regulatory functions[8]. - Pseudogenes may occasionally play minor roles in gene regulation or genome evolution, but RPS12P24 has no evidence supporting such a role as of current knowledge[8]. **Summary:** RPS12P24 is a noncoding pseudogene, not a therapeutic target, receptor, or functional molecule. There is nothing functionally actionable, disease-associated, or druggable about this pseudogene. Its inclusion as a "target" would be incorrect[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S12 pseudogene 24 (RPS12P24).